nir-vana innovation network

According to the International Diabetes Federation’s data, the number of diabetic patients is rapidly increasing every year, with 1 in 11 people being diabetic patients. It is growing significantly in all the age groups ranging from children to elderly. By the year 2030, the number of diabetic patients will be around 578 million (10.2%) in the whole world, and consequently, growth in diabetes-related healthcare products is expected. The Korean company has been researching and developing new microbiome drugs and functional food supplements that can treat various diseases and improve human health by modulating the microbiome through an in-house screening platform for functional materials and metagenome analyses using next-generation genomic analysis technology. The Korean company demonstrated that a probiotic strain isolated from traditional Korean fermented foods helps lower the blood glucose level and glycated hemoglobin and improves insulin resistance and glucose tolerance by animal and human experiments. In animal studies, this strain improved insulin resistance by modulating the microbiome, restoring pancreatic β (beta) cells, and regulating gluconeogenesis (a metabolic process that produces glucose from non-carbohydrate carbon substrates). It has also been shown to regulate glucose levels in pre-diabetic patients. The Korean company can commercialize these probiotics and provide them in powder form. Under commercial agency agreement, the role of a sought-after partner is to: - Distributing raw materials (probiotics) to the European market or - Produce functional food with provided raw materials using its facilities